A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B
Phase 1
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: AHB-137 injectionDrug: Placebo
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AusperBio Therapeutics Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT05717686
- Locations
- 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇨🇳Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
© Copyright 2025. All Rights Reserved by MedPath